Gilder Gagnon Howe & Co. LLC reduced its position in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,393,947 shares of the biopharmaceutical company’s stock after selling 20,684 shares during the period. Alnylam Pharmaceuticals comprises about 1.5% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 12th largest position. Gilder Gagnon Howe & Co. LLC’s holdings in Alnylam Pharmaceuticals were worth $77,350,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of ALNY. Aperio Group LLC raised its position in Alnylam Pharmaceuticals by 129.9% in the first quarter. Aperio Group LLC now owns 14,741 shares of the biopharmaceutical company’s stock worth $925,000 after buying an additional 8,328 shares during the last quarter. BlackRock Inc. raised its position in shares of Alnylam Pharmaceuticals by 29.7% in the first quarter. BlackRock Inc. now owns 69,736 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 15,965 shares in the last quarter. BlackRock Group LTD raised its position in shares of Alnylam Pharmaceuticals by 21.9% in the first quarter. BlackRock Group LTD now owns 519,834 shares of the biopharmaceutical company’s stock valued at $32,630,000 after buying an additional 93,450 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock valued at $115,395,000 after buying an additional 112,252 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 38,162 shares of the biopharmaceutical company’s stock valued at $2,395,000 after buying an additional 450 shares in the last quarter. Institutional investors and hedge funds own 85.95% of the company’s stock.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded down 3.34% on Wednesday, reaching $36.80. The company’s stock had a trading volume of 673,903 shares. The firm’s market cap is $3.15 billion. The firm’s 50 day moving average is $63.40 and its 200-day moving average is $64.84. Alnylam Pharmaceuticals Inc. has a 12 month low of $33.16 and a 12 month high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the business posted ($0.85) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals Inc. will post ($4.68) EPS for the current year.
Several equities analysts recently issued reports on ALNY shares. JPMorgan Chase & Co. lowered Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $83.00 to $51.00 in a research note on Thursday, October 6th. Jefferies Group lowered their price target on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research note on Thursday, October 6th. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, September 30th. FBR & Co restated an “outperform” rating and set a $180.00 price target on shares of Alnylam Pharmaceuticals in a research note on Sunday, July 17th. Finally, Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 25th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $79.50.
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott bought 27,900 shares of the stock in a transaction dated Thursday, October 13th. The shares were bought at an average cost of $37.00 per share, with a total value of $1,032,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.00% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.